STENDRA

This brand name is authorized in Turkey, United States

Active ingredients

The drug STENDRA contains one active pharmaceutical ingredient (API):

1 Avanafil UNII DR5S136IVO - AVANAFIL

Avanafil is a highly selective and potent, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5. When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by avanafil produces increased levels of cGMP in the corpus cavernosum of the penis. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. Read about Avanafil

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
STENDRA Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G04BE10		G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BE Drugs used in erectile dysfunction
Discover more medicines within G04BE10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699809018686, 8699809018693, 8699809018716, 8699809018723, 8699832090888, 8699832090895
Country: US	FDA, National Drug Code	Identifier(s): 72384-751, 72384-752, 72384-753, 76299-320, 76299-321, 76299-322